These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 22169408

  • 1. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
    Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA.
    Int J Antimicrob Agents; 2012 Feb; 39(2):130-4. PubMed ID: 22169408
    [Abstract] [Full Text] [Related]

  • 2. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T.
    J Clin Oncol; 2013 Mar 20; 31(9):1149-56. PubMed ID: 23358983
    [Abstract] [Full Text] [Related]

  • 3. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
    De Waele JJ, Tellado JM, Alder J, Reimnitz P, Jensen M, Hampel B, Arvis P.
    Int J Antimicrob Agents; 2013 Jan 20; 41(1):57-64. PubMed ID: 23153963
    [Abstract] [Full Text] [Related]

  • 4. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA, Mösges R, Desrosiers M, Haverstock D, van Veenhuyzen D, Herman-Gnjidic Z.
    Laryngoscope; 2010 May 20; 120(5):1057-62. PubMed ID: 20422704
    [Abstract] [Full Text] [Related]

  • 5. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program.
    N Engl J Med; 2005 Sep 08; 353(10):977-87. PubMed ID: 16148283
    [Abstract] [Full Text] [Related]

  • 6. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 7. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 8. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B, DRAGON Study Team.
    Int J Antimicrob Agents; 2009 Nov 01; 34(5):439-45. PubMed ID: 19692210
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A, Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group.
    N Engl J Med; 2005 Sep 08; 353(10):988-98. PubMed ID: 16148284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial.
    Wiesner G, Braun SL, Gruber M, Gertler R, Lange R, Tassani P, Martin K.
    J Antimicrob Chemother; 2012 Jan 08; 67(1):230-3. PubMed ID: 21972268
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I, Gogos CA, Bassaris H.
    Int J Antimicrob Agents; 2004 Feb 08; 23(2):129-37. PubMed ID: 15013037
    [Abstract] [Full Text] [Related]

  • 16. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA.
    Cancer; 2005 Jun 15; 103(12):2629-35. PubMed ID: 15856427
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
    Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P.
    BJOG; 2010 Nov 15; 117(12):1475-84. PubMed ID: 20716255
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.